Semaglutide batches out of spec, supplies delayed
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.3 pts less than Nifty 100 and 6.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr Reddys found certain batches of semaglutide out of specification due to an issue with the active pharmaceutical ingredient. Commercial supplies of the product will be delayed until the root cause is identified and fixed. The company says there is no impact on patient safety or on existing global regulatory filings. Management has scheduled a conference call today at 16:30 IST to discuss the matter and answer questions.
Near-term revenue from semaglutide sales may take a hit due to supply delays. Investors should watch the management call for clarity on duration and financial impact.